CervoMed logo
CervoMed
CRVO | NASDAQ
Chart Builder DCF Calculator
$1.67
-$0.02 (-1.18%)
At close: Nov 16, 2026, 4:00 PM ET
$1.65
-$0.02 (-1.16%)
After-hours: Nov 16, 2026, 7:58 PM ET

CervoMed Company Profile

Company profile explained

Company Profile

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Key Executives

Name Position
John J. Alam Co-Founder, Chief Executive Officer, President & Director
William Robert Elder Chief Financial Officer, General Counsel & Corporate Secretary
Claudia Ordonez Senior Vice President of Medical Science
Kelly Blackburn Executive Vice President of Clinical Development
Marinus Verwijs Executive Vice President of Technical Operations
Mark A. De Rosch Executive Vice President of Regulatory, Government Affairs & Program Management
Matthew Winton Chief Commercial & Business Officer
Sylvie L. Gregoire Co-Founder & Director

Latest SEC Filings

Date Type Title
Oct 29, 2026 8-K Current Report
Oct 23, 2026 4 Filing
Oct 23, 2026 4 Filing
Oct 23, 2026 4 Filing
Oct 14, 2026 8-K Current Report
Oct 13, 2026 8-K Current Report
Oct 09, 2026 8-K Current Report
Sep 28, 2026 8-K Current Report
Sep 10, 2026 8-K Current Report
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
View All SEC Filings ➞
CervoMed
CervoMed logo
Country United States
IPO Date May 23, 2008
Industry Biotechnology
Sector Healthcare
Employees 15
CEO John J. Alam

Contact Details

20 Park Plaza Boston, Massachusetts 02116 United States

Stock Details

Ticker Symbol CRVO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001053691
CUSIP Number 15713L109
ISIN Number US15713L1098
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.